HomeGenSight Biologics

GenSight Biologics

GenSight Biologics Reports Long-Term Positive Safety and Visual Acuity Results at Week 96 in Phase I/II Study of GS010 for the Treatment of Leber’s Hereditary Optic Neuropathy

Sustained clinically significant improvement of visual acuity in LHON patients with less than 2 years of visual loss Confirmation of the long-term safety profile of GS010 GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company that...